1
|
Schnute ME, Wennerstål M, Alley J, Bengtsson M, Blinn JR, Bolten CW, Braden T, Bonn T, Carlsson B, Caspers N, Chen M, Choi C, Collis LP, Crouse K, Färnegårdh M, Fennell KF, Fish S, Flick AC, Goos-Nilsson A, Gullberg H, Harris PK, Heasley SE, Hegen M, Hromockyj AE, Hu X, Husman B, Janosik T, Jones P, Kaila N, Kallin E, Kauppi B, Kiefer JR, Knafels J, Koehler K, Kruger L, Kurumbail RG, Kyne RE, Li W, Löfstedt J, Long SA, Menard CA, Mente S, Messing D, Meyers MJ, Napierata L, Nöteberg D, Nuhant P, Pelc MJ, Prinsen MJ, Rhönnstad P, Backström-Rydin E, Sandberg J, Sandström M, Shah F, Sjöberg M, Sundell A, Taylor AP, Thorarensen A, Trujillo JI, Trzupek JD, Unwalla R, Vajdos FF, Weinberg RA, Wood DC, Xing L, Zamaratski E, Zapf CW, Zhao Y, Wilhelmsson A, Berstein G. Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. J Med Chem 2018; 61:10415-10439. [DOI: 10.1021/acs.jmedchem.8b00392] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Tomas Bonn
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Bo Carlsson
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Nicole Caspers
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Ming Chen
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Chulho Choi
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | - Andrew C. Flick
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Steven E. Heasley
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Bolette Husman
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Tomasz Janosik
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | | | | | - Björn Kauppi
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | - John Knafels
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Konrad Koehler
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Lars Kruger
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Ravi G. Kurumbail
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Robert E. Kyne
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Carol A. Menard
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | - Philippe Nuhant
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | - Maria Sjöberg
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Aron Sundell
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | | | - John I. Trujillo
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | - Felix F. Vajdos
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Flick AC, Ding HX, Leverett CA, Kyne RE, Liu KKC, Fink SJ, O’Donnell CJ. Correction to Synthetic Approaches to the New Drugs Approved During 2015. J Med Chem 2017; 60:8680. [DOI: 10.1021/acs.jmedchem.7b01452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Fadeyi OO, Hoth LR, Choi C, Feng X, Gopalsamy A, Hett EC, Kyne RE, Robinson RP, Jones LH. Covalent Enzyme Inhibition through Fluorosulfate Modification of a Noncatalytic Serine Residue. ACS Chem Biol 2017; 12:2015-2020. [PMID: 28718624 DOI: 10.1021/acschembio.7b00403] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Irreversible enzyme inhibitors and covalent chemical biology probes often utilize the reaction of a protein cysteine residue with an appropriately positioned electrophile (e.g., acrylamide) on the ligand template. However, cysteine residues are not always available for site-specific protein labeling, and therefore new approaches are needed to expand the toolkit of appropriate electrophiles ("warheads") that target alternative amino acids. We previously described the rational targeting of tyrosine residues in the active site of a protein (the mRNA decapping scavenger enzyme, DcpS) using inhibitors armed with a sulfonyl fluoride electrophile. These inhibitors subsequently enabled the development of clickable probe technology to measure drug-target occupancy in live cells. Here we describe a fluorosulfate-containing inhibitor (aryl fluorosulfate probe (FS-p1)) with excellent chemical and metabolic stability that reacts selectively with a noncatalytic serine residue in the same active site of DcpS as confirmed by peptide mapping experiments. Our results suggest that noncatalytic serine targeting using fluorosulfate electrophilic warheads could be a suitable strategy for the development of covalent inhibitor drugs and chemical probes.
Collapse
Affiliation(s)
- Olugbeminiyi O. Fadeyi
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lise R. Hoth
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Chulho Choi
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xidong Feng
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ariamala Gopalsamy
- Medicine
Design, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Erik C. Hett
- Medicine
Design, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Robert E. Kyne
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ralph P. Robinson
- Medicine
Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lyn H. Jones
- Medicine
Design, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
4
|
Affiliation(s)
- Andrew C. Flick
- Groton
Laboratories, Pfizer Worldwide Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Hong X. Ding
- Pharmacodia (Beijing) Co., Ltd., Beijing, 100085, China
| | - Carolyn A. Leverett
- Groton
Laboratories, Pfizer Worldwide Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert E. Kyne
- Celgene Corporation, 200 Cambridge
Park Drive, Cambridge, Massachusetts 02140, United States
| | - Kevin K. -C. Liu
- China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai, 201203, China
| | | | - Christopher J. O’Donnell
- Groton
Laboratories, Pfizer Worldwide Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
5
|
Gopalsamy A, Narayanan A, Liu S, Parikh MD, Kyne RE, Fadeyi O, Tones MA, Cherry JJ, Nabhan JF, LaRosa G, Petersen DN, Menard C, Foley TL, Noell S, Ren Y, Loria PM, Maglich-Goodwin J, Rong H, Jones LH. Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA). J Med Chem 2017; 60:3094-3108. [DOI: 10.1021/acs.jmedchem.7b00124] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Ariamala Gopalsamy
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Arjun Narayanan
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Shenping Liu
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mihir D. Parikh
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert E. Kyne
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Olugbeminiyi Fadeyi
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael A. Tones
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jonathan J. Cherry
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Joseph F. Nabhan
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gregory LaRosa
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Donna N. Petersen
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Carol Menard
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Timothy L. Foley
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Stephen Noell
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Yong Ren
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paula M. Loria
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jodi Maglich-Goodwin
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Haojing Rong
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lyn H. Jones
- Medicine
Design and ‡Rare Disease Research Unit, #Pharmacokinetics and Drug Metabolism, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Medicine Design and †Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
6
|
Hett EC, Kyne RE, Gopalsamy A, Tones MA, Xu H, Thio GL, Nolan E, Jones LH. Selectivity Determination of a Small Molecule Chemical Probe Using Protein Microarray and Affinity Capture Techniques. ACS Comb Sci 2016; 18:611-615. [PMID: 27494431 DOI: 10.1021/acscombsci.6b00089] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Small molecule selectivity is an essential component of candidate drug selection and target validation. New technologies are required to better understand off-target effects, with particular emphasis needed on broad protein profiling. Here, we describe the use of a tritiated chemical probe and a 9000 human protein microarray to discern the binding selectivity of an inhibitor of the mRNA decapping scavenger enzyme DcpS. An immobilized m7GTP resin was also used to assess the selectivity of a DcpS inhibitor against mRNA cap-associated proteins in whole cell extracts. These studies confirm the exquisite selectivity of diaminoquinazoline DcpS inhibitors, and highlight the utility of relatively simple protein microarray and affinity enrichment technologies in drug discovery and chemical biology.
Collapse
Affiliation(s)
- Erik C. Hett
- Medicine
Design, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Robert E. Kyne
- Medicine
Design, Pfizer, East Point Road, Groton, Connecticut 06340, United States
| | - Ariamala Gopalsamy
- Medicine
Design, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Michael A. Tones
- Rare
Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Hua Xu
- Medicine
Design, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Guene L. Thio
- Protein
and Cell Analysis, Life Sciences Solutions, Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, California 92008, United States
| | - Edward Nolan
- Protein
and Cell Analysis, Life Sciences Solutions, Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, California 92008, United States
| | - Lyn H. Jones
- Medicine
Design, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
7
|
Fadeyi O, Parikh MD, Chen MZ, Kyne RE, Taylor AP, O'Doherty I, Kaiser SE, Barbas S, Niessen S, Shi M, Weinrich SL, Kath JC, Jones LH, Robinson RP. Chemoselective Preparation of Clickable Aryl Sulfonyl Fluoride Monomers: A Toolbox of Highly Functionalized Intermediates for Chemical Biology Probe Synthesis. Chembiochem 2016; 17:1925-1930. [PMID: 27504718 DOI: 10.1002/cbic.201600427] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Indexed: 11/08/2022]
Abstract
Sulfonyl fluoride (SF)-based activity probes have become important tools in chemical biology. Herein, exploiting the relative chemical stability of SF to carry out a number of unprecedented SF-sparing functional group manipulations, we report the chemoselective synthesis of a toolbox of highly functionalized aryl SF monomers that we used to quickly prepare SF chemical biology probes. In addition to SF, the monomers bear an embedded click handle (a terminal alkyne that can perform copper(I)-mediated azide-alkyne cycloaddition). The monomers can be used either as fragments to prepare clickable SF analogues of drugs (biologically active compounds) bearing an aryl ring or, alternatively, attached to drugs as minimalist clickable aryl SF substituents.
Collapse
Affiliation(s)
| | - Mihir D Parikh
- Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA
| | - Ming Z Chen
- Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA
| | - Robert E Kyne
- Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA
| | | | - Inish O'Doherty
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Stephen E Kaiser
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Sabrina Barbas
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Sherry Niessen
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Manli Shi
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Scott L Weinrich
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - John C Kath
- Oncology RU Medicinal Chemistry, Pfizer Inc., 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Lyn H Jones
- Medicine Design, Pfizer Inc., 610 Main Street, Cambridge, MA, 02139, USA
| | - Ralph P Robinson
- Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA.
| |
Collapse
|
8
|
Xu H, Gopalsamy A, Hett EC, Salter S, Aulabaugh A, Kyne RE, Pierce B, Jones LH. Cellular thermal shift and clickable chemical probe assays for the determination of drug-target engagement in live cells. Org Biomol Chem 2016; 14:6179-83. [DOI: 10.1039/c6ob01078d] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Proof of drug-target engagement in physiologically-relevant contexts is a key pillar of successful therapeutic target validation.
Collapse
Affiliation(s)
- Hua Xu
- Worldwide Medicinal Chemistry
- Cambridge
- USA
| | | | | | | | - Ann Aulabaugh
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Groton
- USA
| | | | | | | |
Collapse
|
9
|
Ding HX, Leverett CA, Kyne RE, Liu KKC, Fink SJ, Flick AC, O’Donnell CJ. Synthetic approaches to the 2013 new drugs. Bioorg Med Chem 2015; 23:1895-922. [DOI: 10.1016/j.bmc.2015.02.056] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Revised: 02/20/2015] [Accepted: 02/26/2015] [Indexed: 12/31/2022]
|
10
|
Hett EC, Xu H, Geoghegan KF, Gopalsamy A, Kyne RE, Menard CA, Narayanan A, Parikh MD, Liu S, Roberts L, Robinson RP, Tones MA, Jones LH. Rational targeting of active-site tyrosine residues using sulfonyl fluoride probes. ACS Chem Biol 2015; 10:1094-8. [PMID: 25571984 DOI: 10.1021/cb5009475] [Citation(s) in RCA: 133] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
This work describes the first rational targeting of tyrosine residues in a protein binding site by small-molecule covalent probes. Specific tyrosine residues in the active site of the mRNA-decapping scavenger enzyme DcpS were modified using reactive sulfonyl fluoride covalent inhibitors. Structure-based molecular design was used to create an alkyne-tagged probe bearing the sulfonyl fluoride warhead, thus enabling the efficient capture of the protein from a complex proteome. Use of the probe in competition experiments with a diaminoquinazoline DcpS inhibitor permitted the quantification of intracellular target occupancy. As a result, diaminoquinazoline upregulators of survival motor neuron protein that are used for the treatment of spinal muscular atrophy were confirmed as inhibitors of DcpS in human primary cells. This work illustrates the utility of sulfonyl fluoride probes designed to react with specific tyrosine residues of a protein and augments the chemical biology toolkit by these probes uses in target validation and molecular pharmacology.
Collapse
Affiliation(s)
- Erik C. Hett
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Hua Xu
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kieran F. Geoghegan
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ariamala Gopalsamy
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert E. Kyne
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Carol A. Menard
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Arjun Narayanan
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mihir D. Parikh
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Shenping Liu
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lee Roberts
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ralph P. Robinson
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael A. Tones
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lyn H. Jones
- Worldwide
Medicinal Chemistry and ‡Rare Disease Research Unit, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Structural Biology and Biophysics, Worldwide Medicinal Chemistry, ∥Worldwide Medicinal
Chemistry, and ⊥Primary Pharmacology Group, Pfizer, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
11
|
Abstract
1,3-Diols engage in ruthenium-catalyzed hydrogen transfer in the presence of alkyl hydrazines to provide 1,4-disubstituted pyrazoles. Regioselective synthesis of unsymmetrical pyrazoles from β-hydroxy ketones is also described.
Collapse
Affiliation(s)
- Daniel C Schmitt
- Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Alexandria P Taylor
- Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Andrew C Flick
- Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert E Kyne
- Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
12
|
Xu H, Hett EC, Gopalsamy A, Parikh MD, Geoghegan KF, Kyne RE, Menard CA, Narayanan A, Robinson RP, Johnson DS, Tones MA, Jones LH. A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS. Mol BioSyst 2015; 11:2709-12. [DOI: 10.1039/c5mb00288e] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A photoaffinity library expedited the discovery of a site-specific DcpS probe.
Collapse
Affiliation(s)
- Hua Xu
- Worldwide Medicinal Chemistry
- Pfizer Inc
- Cambridge
- USA
| | - Erik C. Hett
- Worldwide Medicinal Chemistry
- Pfizer Inc
- Cambridge
- USA
| | | | | | - Kieran F. Geoghegan
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Pfizer Inc
- Groton CT
- USA
| | | | | | | | | | | | | | - Lyn H. Jones
- Worldwide Medicinal Chemistry
- Pfizer Inc
- Cambridge
- USA
| |
Collapse
|
13
|
Abstract
Catalytic enantioselective allyl-allyl cross-coupling of a borylated allylboronate reagent gives versatile borylated chiral 1,5-hexadienes. These compounds may be manipulated in a number of useful ways to give functionalized chiral building blocks for asymmetric synthesis.
Collapse
Affiliation(s)
- Hai Le
- Department of Chemistry, Boston College, Chestnut Hill, Massachusetts 02467, United States
| | | | | | | |
Collapse
|
14
|
Zhang P, Le H, Kyne RE, Morken JP. Enantioselective construction of all-carbon quaternary centers by branch-selective Pd-catalyzed allyl-allyl cross-coupling. J Am Chem Soc 2011; 133:9716-9. [PMID: 21648464 PMCID: PMC3131072 DOI: 10.1021/ja2039248] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The Pd-catalyzed cross-coupling of racemic tertiary allylic carbonates and allylboronates is described. This reaction generates all-carbon quaternary centers in a highly regioselective and enantioselective fashion. The outcome of these reactions is consistent with a process that proceeds by way of 3,3'-reductive elimination of bis(η(1)-allyl)palladium intermediates. Strategies for distinguishing the product alkenes and application to the synthesis of (+)-α-cuparenone are also described.
Collapse
Affiliation(s)
- Ping Zhang
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA 02467
| | - Hai Le
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA 02467
| | - Robert E. Kyne
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA 02467
| | - James P. Morken
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA 02467
| |
Collapse
|
15
|
Kyne RE, Ryan MC, Kliman LT, Morken JP. Allylation of nitrosobenzene with pinacol allylboronates. A regioselective complement to peroxide oxidation. Org Lett 2010; 12:3796-9. [PMID: 20687578 DOI: 10.1021/ol101472k] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Addition of nitrosobenzene to pinacol allylboronates leads to oxidation of the organoboron with concomitant rearrangement of the substrate alkene. This reaction appears to proceed by allylboration of the nitroso group in analogy to carbonyl and imine allylation reactions. Remarkably, the N-O bond is cleaved during the reaction such that simple alcohols are the final reaction product.
Collapse
Affiliation(s)
- Robert E Kyne
- Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467, USA
| | | | | | | |
Collapse
|
16
|
Abstract
A variety of 1-allenyl-2-propargyl-substituted cyclopentanol derivatives were found to undergo facile intramolecular microwave-assisted 2+2 alleneyne cycloaddition reactions to generate tricyclic 5-6-4 ring systems present in the sterpurenes.
Collapse
Affiliation(s)
- Timo V Ovaska
- Department of Chemistry, Connecticut College, 270 Mohegan Avenue, New London, CT 06320, USA
| | | |
Collapse
|
17
|
Li X, Kyne RE, Ovaska TV. Synthesis of seven-membered carbocyclic rings via a microwave-assisted tandem oxyanionic 5-exo dig cyclization-claisen rearrangement process. J Org Chem 2007; 72:6624-7. [PMID: 17655366 PMCID: PMC2523263 DOI: 10.1021/jo0710432] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Appropriately substituted 1-alkenyl-4-pentyn-1-ol systems, readily prepared from simple starting materials, serve as useful precursors to a number of substituted cyclohept-4-enone derivatives via a microwave-assisted tandem oxyanionic 5-exo cyclization/Claisen rearrangement sequence. The reactions involving terminally substituted 4-pentyn-1-ols were found to be highly stereoselective, with the alpha and beta groups in the final product showing a strong preference for the trans orientation.
Collapse
Affiliation(s)
- Xin Li
- Department of Chemistry, Connecticut College, 270 Mohegan Avenue, New London, Connecticut 06320, USA
| | | | | |
Collapse
|
18
|
Abstract
A straightforward approach toward the total synthesis of frondosin C is described. This strategy involves a key one-pot, microwave-assisted 5-exo cyclization-Claisen rearrangement sequence that was used for the expedient assembly of the frondosic C scaffold. Subsequent manipulation of the tetracyclic core allowed the synthesis of an advanced intermediate bearing the characteristic diene moiety in the B ring. [reaction: see text]
Collapse
Affiliation(s)
- Xin Li
- Department of Chemistry, Connecticut College, 270 Mohegan Avenue, New London, CT 06320, USA
| | | | | |
Collapse
|